E. Ohman J:or Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-8,300
| Closed | -$733K | – | 430 |
|
|
2021
Q4 | $733K | Hold |
8,300
| – | – | 0.02% | 364 |
|
|
2021
Q3 | $642K | Sell |
8,300
-1,300
| -14% | -$103K | 0.02% | 366 |
|
|
2021
Q2 | $801K | Hold |
9,600
| – | – | 0.03% | 330 |
|
|
2021
Q1 | $725K | Hold |
9,600
| – | – | 0.03% | 315 |
|
|
2020
Q4 | $842K | Buy |
9,600
+2,500
| +35% | +$198K | 0.03% | 251 |
|
|
2020
Q3 | $540K | Sell |
7,100
-258,137
| -97% | -$26.1M | 0.03% | 273 |
|
|
2020
Q2 | $32.7M | Buy |
265,237
+27,317
| +11% | +$2.71M | 1.88% | 15 |
|
|
2020
Q1 | $20.1M | Buy |
237,920
+27,497
| +13% | +$2.37M | 1.47% | 20 |
|
|
2019
Q4 | $17.8M | Buy |
210,423
+39,830
| +23% | +$3.01M | 0.98% | 27 |
|
|
2019
Q3 | $11.5M | Buy |
170,593
+166,393
| +3,962% | +$12.8M | 0.72% | 33 |
|
|
2019
Q2 | $360K | Sell |
4,200
-4,100
| -49% | -$351K | 0.02% | 285 |
|
|
2019
Q1 | $737K | Hold |
8,300
| – | – | 0.05% | 193 |
|
|
2018
Q4 | $707K | Hold |
8,300
| – | – | 0.05% | 181 |
|
|
2018
Q3 | $805K | Buy |
8,300
+800
| +11% | +$79.9K | 0.05% | 192 |
|
|
2018
Q2 | $707K | Buy |
7,500
+2,700
| +56% | +$236K | 0.05% | 195 |
|
|
2018
Q1 | $389K | Sell |
4,800
-1,200
| -20% | -$103K | 0.03% | 301 |
|
|
2017
Q4 | $535K | Buy |
6,000
+900
| +18% | +$78.3K | 0.04% | 252 |
|
|
2017
Q3 | $475K | Buy |
5,100
+100
| +2% | +$8.84K | 0.04% | 268 |
|
|
2017
Q2 | $454K | Hold |
5,000
| – | – | 0.05% | 267 |
|
|
2017
Q1 | $439K | Buy |
5,000
+1,700
| +52% | +$151K | 0.05% | 269 |
|
|
2016
Q4 | $273K | Hold |
3,300
| – | – | 0.04% | 329 |
|
|
2016
Q3 | $305K | Hold |
3,300
| – | – | 0.05% | 281 |
|
|
2016
Q2 | $257K | Hold |
3,300
| – | – | 0.04% | 297 |
|
|
2016
Q1 | $272K | Hold |
3,300
| – | – | 0.05% | 267 |
|
|
2015
Q4 | $346K | Hold |
3,300
| – | – | 0.06% | 232 |
|
|
2015
Q3 | $348K | Hold |
3,300
| – | – | 0.09% | 212 |
|
|
2015
Q2 | $451K | Hold |
3,300
| – | – | 0.11% | 189 |
|
|
2015
Q1 | $411K | Hold |
3,300
| – | – | 0.1% | 212 |
|
|
2014
Q4 | $298K | Hold |
3,300
| – | – | 0.07% | 262 |
|
|
2014
Q3 | $238K | Hold |
3,300
| – | – | 0.06% | 316 |
|
|
2014
Q2 | $205K | Hold |
3,300
| – | – | 0.05% | 363 |
|
|
2014
Q1 | $225K | Hold |
3,300
| – | – | 0.06% | 332 |
|
|
2013
Q4 | $229K | Hold |
3,300
| – | – | 0.05% | 328 |
|
|
2013
Q3 | $238K | Hold |
3,300
| – | – | 0.06% | 320 |
|
|
2013
Q2 | $184K | Buy |
+3,300
| New | +$206K | 0.05% | 365 |
|
Other funds holding BMRN
BBA
E. Ohman J:or Asset Management's BMRN Position: Q1 2022 in Review
E. Ohman J:or Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 8,300 shares — an estimated $733K sold.
E. Ohman J:or Asset Management first reported a position in BMRN in Q2 2013 and held it in 35 quarters. The position peaked at $32.7M in Q2 2020. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.
- E. Ohman J:or Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
- E. Ohman J:or Asset Management sold 8,300 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $733K.
- E. Ohman J:or Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 35 quarters.
- E. Ohman J:or Asset Management's BioMarin Pharmaceuticals position peaked at $32.7M in Q2 2020.
- 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.
Based on E. Ohman J:or Asset Management's 13F filing for Q1 2022, filed 5 Apr 2024.